Angiodynamics (ANGO) Equity Average (2011 - 2026)

Angiodynamics (ANGO) has 16 years of Equity Average data on file, last reported at $174.8 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 6.16% year-over-year to $174.8 million; the trailing twelve-month figure through Feb 2026 stood at $174.8 million (down 6.16% YoY), and the FY2025 full-year result was $194.3 million, down 33.45% from the prior year.
• Equity Average for Q1 2026 stood at $174.8 million, down from $177.6 million in the prior quarter.
• Across five years, Equity Average topped out at $431.0 million in Q1 2022 and bottomed at $174.8 million in Q1 2026.
• The 5-year median for Equity Average is $310.0 million (2024), against an average of $300.9 million.
• The widest annual swing landed in 2023, when Equity Average advanced 0.86%; it then slumped 53.76% in 2024.
• A 5-year view of Equity Average shows it stood at $411.0 million in 2022, then climbed by 0.86% to $414.5 million in 2023, then slumped by 53.76% to $191.7 million in 2024, then declined by 7.35% to $177.6 million in 2025, then declined by 1.55% to $174.8 million in 2026.
• The last three Equity Average figures came in at $174.8 million (Q1 2026), $177.6 million (Q4 2025), and $180.9 million (Q3 2025), per Business Quant data.

Peer Comparison